Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer

Recruiting

Phase 1

Phase 2

AU-007Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer

Sponsor:

Aulos Bioscience, Inc.

Code:

NCT05267626

Conditions

Advanced Solid Tumor

Metastatic Cancer

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

AU-007

Aldesleukin

Avelumab

Nivolumab

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-04-26. This information was provided to ClinicalTrials.gov by Aulos Bioscience, Inc. on 2025-04-06.